Tamil Arasu
Investigator / Chemist, Ph.D.
CDER Office of Compliance, Office of Manufacturing Quality (Rockville, MD)
Veteran international drug investigator with 74 483s across 11 countries — specialises in laboratory controls, OOS investigations, and data integrity, with landmark inspections uncovering undisclosed warehouses and falsified records.
Inspection Approach
How Tamil Inspects
Arasu brings deep analytical chemistry expertise to his inspections, with a primary focus on laboratory controls and the scientific soundness of OOS/OOT investigations. He systematically traces investigation conclusions back through the data — interviewing analysts, reviewing chromatographic raw data, and demanding statistical evidence for method equivalency claims rather than accepting simple RSD comparisons.
His inspection methodology has evolved to include aggressive physical verification. At Hetero Labs Unit-IX in 2025, his team discovered an undisclosed warehouse containing undocumented API drums and an unregistered testing laboratory — findings that transformed a routine inspection into a major enforcement action. He cross-references batch records against physical inventory, flagging any unexplained overages or discrepancies in drum counts.
Arasu frequently co-investigates with Pratik S. Upadhyay, creating a formidable team that combines Arasu's laboratory and analytical depth with Upadhyay's data integrity and cleaning validation expertise. Together they have conducted inspections at Hetero Labs, Lupin, and Sri Krishna Pharmaceuticals, with their joint findings consistently generating multi-page 483s.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Hetero Labs Limited, Unit-IX
- Undisclosed warehouse discovered containing undocumented API drums with falsified/defaced labels
- Unregistered testing laboratory used for API testing outside the quality system
- Batch record discrepancies showing unexplained overages in raw material reconciliation
- 14-page Form 483 documenting systematic quality system failures
Lupin Limited
- Mutagenic impurity failures across multiple batches of capsules — over 50% batch failure rate
- No investigations conducted for failing batches; continued manufacturing and distribution
- No Health Hazard Assessment performed despite known impurity failures
- Delayed corrective actions on OOS dissolution results across multiple products
- 18-page Form 483 with co-investigator Pratik S. Upadhyay
Jubilant Generics Limited
- Cleaning validation deficiencies with unknown peaks in cleaning verification swab samples
- Inadequate investigation of unknown chromatographic peaks during equipment cleaning verification
- Data integrity concerns across laboratory documentation systems
Sri Krishna Pharmaceuticals Limited
- Laboratory controls and documentation deficiencies across analytical testing
- Co-investigated with Pratik S. Upadhyay — combined findings on lab and data integrity
Aurobindo Pharma Limited
- Team inspection with 3 investigators identifying multi-system compliance failures
- Laboratory controls and manufacturing documentation deficiencies
Akorn Inc.
- 45-day inspection — one of the longest in Arasu's career
- Sterile drug manufacturing deficiencies across multiple product lines
Pre-Inspection Preparation
How to Prepare
- 1 Fortify OOS/OOT investigation programmes — Arasu consistently identifies inadequate root cause analysis and delayed investigations. Ensure every OOS extends into manufacturing when laboratory error is not confirmed.
- 2 Audit chromatographic integration practices — he specifically checks for misuse of "inhibit integration" functions and unknown/unidentified peaks in chromatographic data.
- 3 Ensure all testing laboratories are registered and documented — the Hetero Labs inspection revealed an undisclosed lab used outside the quality system.
- 4 Validate analytical method equivalency rigorously — he expects statistical equivalency or non-inferiority analysis, not just RSD comparisons.
- 5 Reconcile batch records against actual yields — Arasu cross-references documented quantities with physical inventory. Any unexplained overages will be flagged.
- 6 Prepare impurity control documentation — mutagenic impurity compliance, nitrosamine testing, and unknown peak identification are recurring focus areas.
- 7 Review cleaning validation for unknown peaks — swab samples showing unidentified chromatographic peaks must be investigated and identified.
- 8 Ensure all warehouses and storage facilities are registered and documented in the quality system — undisclosed storage locations are a critical finding.
- 9 Verify that complaint handling includes Health Hazard Assessments when product quality failures are confirmed.
- 10 Maintain controlled, pre-numbered documents for all raw data — uncontrolled notebooks and loose papers will trigger data integrity citations.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Tamil Arasu — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
